Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5347275 | 0.79 | POLB (0.50) | LTA4HHRH3CHRNB2CHRNA4 | |
| SCHEMBL28709343 | 0.79 | PARP1 (0.40) | CXCR4LTA4HHRH3PARP1CHRNB2 | |
| SCHEMBL18078 | 0.79 | CHRNB4 (0.48) | CXCR4LTA4HKDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL29086107 | 0.75 | KDM1A (0.40) | LTA4HKDM1AMAOAMAOBBACE1 | |
| SCHEMBL27854563 | 0.74 | SLC6A2 (0.42) | KDM1AMAOAMAOBBACE1 | |
| SCHEMBL818603 | 0.74 | LTA4H (0.43) | LTA4HHRH3PARP1CYP2D6 | |
| SCHEMBL14698505 | 0.74 | GBA1 (0.46) | KDM1AMAOAMAOBHRH3BACE1 | |
| SCHEMBL2246688 | 0.72 | PLG (0.45) | LTA4HHRH3PARP1CYP2D6 | |
| SCHEMBL7501787 | 0.72 | LTA4H (0.41) | LTA4HHRH3PARP1CYP2D6 | |
| SCHEMBL27600947 | 0.72 | LTA4H (0.41) | LTA4HHRH3PARP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746072-B1 | 2H-INDAZOLE DERIVATIVES AS CDK4 AND CDK6 INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11352341-B2 | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof | BETA PHARMA, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-110117273-B | 2H-indazole derivatives as Cyclin Dependent Kinase (CDK) inhibitors and their medical use | 贝达医药公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3191469-B1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210139459-A1 | 2H-INDAZOLE DERIVATIVES AS CDK4 AND CDK6 INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA INC (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3746072-A1 | 2H-INDAZOLE DERIVATIVES AS CDK4 AND CDK6 INHIBITORS AND THERAPEUTIC USES THEREOF | Beta Pharma, Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| CN-111989099-A | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and their therapeutic use | 贝塔制药有限公司 | 2020-11-24 | — | — | CN | disclosed |
| WO-2019148161-A1 | 2H-INDAZOLE DERIVATIVES AS CDK4 AND CDK6 INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-10239864-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148431-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBOTORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-9878994-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| EP-3191469-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | Beta Pharma, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016014904-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239864-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | CDK4, CDK6, CDK2 | CXCR4 934/4885LTA4H 1194/4885KDM1A 878/4885 |
| US-11352341-B2 | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof | CDK4, CDK6, CDK3 | CXCR4 865/4885LTA4H 1639/4885KDM1A 583/4885 |
| US-20180148431-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBOTORS AND THERAPEUTIC USES THEREOF | CDK4, CDK2, CDK3 | CXCR4 1205/4885LTA4H 1462/4885KDM1A 1096/4885 |
| US-20210139459-A1 | 2H-INDAZOLE DERIVATIVES AS CDK4 AND CDK6 INHIBITORS AND THERAPEUTIC USES THEREOF | CDK4, CDK6, CDK3 | CXCR4 865/4885LTA4H 1639/4885KDM1A 583/4885 |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | CDK4, CDK3, CDK6 | CXCR4 896/4885LTA4H 1089/4885KDM1A 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.